Briacell Short Term Debt vs Current Deferred Revenue Analysis
BCTX Stock | USD 0.53 0.03 5.54% |
Briacell Therapeutics financial indicator trend analysis is way more than just evaluating Briacell Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Briacell Therapeutics is a good investment. Please check the relationship between Briacell Therapeutics Short Term Debt and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Short Term Debt vs Current Deferred Revenue
Short Term Debt vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Briacell Therapeutics Short Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Briacell Therapeutics' Short Term Debt and Current Deferred Revenue is 0.88. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Briacell Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Briacell Therapeutics' Short Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Briacell Therapeutics Corp are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Short Term Debt i.e., Briacell Therapeutics' Short Term Debt and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.88 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Short Term Debt
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Briacell Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Briacell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, Briacell Therapeutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 77 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 4.2 M in 2024.
Briacell Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Briacell Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Briacell Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 478.3K | 58.0M | 42.6M | 27.2M | 5.9M | 10.3M | |
Total Current Liabilities | 3.6M | 556.8K | 941.1K | 1.8M | 7.5M | 7.8M | |
Total Stockholder Equity | (3.3M) | 57.3M | 10.3M | (3.8M) | (2.4M) | (2.3M) | |
Net Debt | 209.3K | (57.2M) | (41.0M) | (21.3M) | (862.1K) | (905.2K) | |
Retained Earnings | (16.6M) | (15.8M) | (60.3M) | (80.7M) | (85.4M) | (81.2M) | |
Accounts Payable | 4.2K | 214.1K | 463.3K | 1.1M | 7.2M | 7.5M | |
Cash | 19.5K | 57.3M | 41.0M | 21.3M | 862.1K | 819.0K | |
Non Current Assets Total | 238.9K | 245.6K | 230.3K | 215.1K | 2.2M | 1.2M | |
Cash And Short Term Investments | 19.5K | 57.3M | 41.0M | 21.3M | 862.1K | 819.0K | |
Common Stock Shares Outstanding | 713.9K | 4.5M | 15.5M | 15.6M | 16.5M | 17.3M | |
Liabilities And Stockholders Equity | 478.3K | 58.0M | 42.6M | 27.2M | 5.9M | 10.3M | |
Non Current Liabilities Total | 142.8K | 225.4K | 31.3M | 29.1M | 1.1M | 1.0M | |
Other Stockholder Equity | 2.2M | 39.0M | 5.2M | 7.4M | 11.0M | 8.1M | |
Total Liab | 3.8M | 782.2K | 32.2M | 30.9M | 8.6M | 4.8M | |
Total Current Assets | 239.4K | 57.8M | 42.3M | 26.9M | 3.7M | 3.5M | |
Net Receivables | 20.6K | 12.6K | 24.1K | 717.7K | 1.4M | 1.4M | |
Other Current Liab | 3.4M | 480.7K | 741.8K | 677.7K | 290.4K | 275.9K | |
Inventory | (305.0) | 1.0 | (24.1K) | (18.9K) | (1.4M) | (1.3M) | |
Other Current Assets | 199.7K | 516.9K | 1.3M | 5.0M | 1.4M | 721.5K | |
Accumulated Other Comprehensive Income | (81.0K) | (94.5K) | (127.0K) | (138.7K) | (124.8K) | (118.6K) | |
Intangible Assets | 238.9K | 245.6K | 230.3K | 215.1K | 199.8K | 182.9K | |
Net Tangible Assets | (1.2M) | (4.7M) | 57.0M | 10.1M | 11.6M | 11.5M | |
Net Invested Capital | (4.1M) | 57.3M | 10.3M | (3.8M) | (2.4M) | (2.3M) | |
Net Working Capital | (4.5M) | 57.2M | 41.4M | 25.1M | (3.8M) | (3.6M) | |
Common Stock | 11.2M | 54.8M | 65.6M | 69.6M | 72.2M | 41.0M | |
Capital Stock | 11.2M | 54.8M | 65.6M | 69.6M | 72.2M | 45.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.